We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VPG:NYSEVishay Precision Group, Inc. Analysis

Data as of 2026-06-07 - not real-time

$117.51

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Vishay Precision Group reported a robust first‑quarter with revenue of $84.4 M, up 18 % YoY, and bookings topping $100 M, pushing gross margin to roughly 39 % – a clear beat on the backdrop of a 17.6 % annual revenue growth rate. The stock is trading at $117.51, well above its DCF‑derived fair value of $21.44 and carries a trailing P/E of 261 versus an industry average of 32, indicating significant overvaluation. Technicals show price comfortably above the 20‑day ($108.65), 50‑day ($75.12) and 200‑day ($47.45) SMAs, supporting a bullish trend, yet the MACD histogram is negative and the signal line is bearish, while RSI sits at 64.4, hinting at near‑overbought conditions. Volume has been decreasing, and the 30‑day volatility spikes above 100 %, compounded by a high beta of 2.54, underscoring elevated market risk.
The company’s fundamentals reveal thin operating margins (0.9 %), modest ROE (1.8 %), and no dividend, limiting income appeal. Despite strong top‑line momentum and diversified exposure across North America, Europe, Israel and Asia, the valuation gap and heightened volatility suggest caution. Investors should weigh the growth narrative against the stark pricing disconnect and the bearish short‑term technical signals before positioning.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price far above DCF fair value
  • bearish MACD signal and high RSI
  • elevated volatility and decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • strong revenue and order growth
  • improving gross margin
  • still significant valuation premium

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • diversified end‑market exposure
  • potential for margin expansion
  • high beta and price correction risk

Key Metrics & Analysis

Financial Health

Revenue Growth17.60%
Profit Margin1.85%
P/E Ratio261.1
ROE1.82%
ROA1.42%
Debt/Equity13.27
P/B Ratio4.7
Op. Cash Flow$8.5M
Free Cash Flow$9.1M
Industry P/E32.6

Technical Analysis

TrendBullish
RSI64.4
Support$63.45
Resistance$136.21
MA 20$108.65
MA 50$75.12
MA 200$47.45
MACDBearish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Fair Value$21.44
Target Price$94.67
Upside/Downside-19.44%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.54
Volatility105.68%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.